Zadik Hazan
Chief Tech/Sci/R&D Officer at Hy BioPharma, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Yitzhak Peterburg | M | 73 |
Regenera Pharma Ltd.
 Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | - |
| Michael Steinberg | M | - |
Hy BioPharma, Inc.
 Hy BioPharma, Inc. Medical DistributorsDistribution Services Hy BioPharma, Inc. develops drug technology solutions. The company develops Hypericin for the treatment of cancer, autoimmune disorders, and inflammation. It was established in 2006 and is headquartered in Jamison, PA. | - |
| Sharon Falach-Kovalsky | F | - |
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | - |
| Marius Nacht | M | - |
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | - |
| Shlomo Shalev | M | 62 |
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | - |
| Alfonso Tobia | M | - |
Hy BioPharma, Inc.
Hy BioPharma, Inc. Medical DistributorsDistribution Services Hy BioPharma, Inc. develops drug technology solutions. The company develops Hypericin for the treatment of cancer, autoimmune disorders, and inflammation. It was established in 2006 and is headquartered in Jamison, PA. | - |
| Bernard Cabana | M | - |
Hy BioPharma, Inc.
Hy BioPharma, Inc. Medical DistributorsDistribution Services Hy BioPharma, Inc. develops drug technology solutions. The company develops Hypericin for the treatment of cancer, autoimmune disorders, and inflammation. It was established in 2006 and is headquartered in Jamison, PA. | - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| Israel | 4 | 57.14% |
| United States | 3 | 42.86% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Zadik Hazan
- Personal Network
